3/2/2021 7:19:27 AM
TherapeuticsMD Q4 Loss Per Share $0.15 Vs Loss $0.19 Last Year
2/11/2021 9:05:12 AM
TherapeuticsMD Announces Pricing Of $110 Mln Public Offering Of Common Stock
11/10/2020 9:02:03 AM
TherapeuticsMD Prices Underwritten Public Offering Of About 23.4 Mln Shares For $30 Mln
11/9/2020 6:58:41 AM
TherapeuticsMD Q3 Loss Per Share $0.12 Vs Loss $0.13 Last Year
8/25/2020 7:33:14 AM
Knight And TherapeuticsMD Announce Health Canada Approval Of IMVEXXY
8/6/2020 7:18:03 AM
TherapeuticsMD Q2 Net Loss $52 Mln Vs Net Loss $55.2 Mln Last Year
6/1/2020 6:58:12 AM
TherapeuticsMD Appoints James D'Arecca As CFO And Retirement Of Daniel Cartwright As CFO
5/6/2020 6:57:40 AM
TherapeuticsMD Q1 Loss Per Share $0.21 Vs Loss $0.16 Last Year
4/22/2020 6:54:36 AM
TherapeuticsMD Names Karen Ling To Board Of Directors
3/24/2020 7:52:23 AM
TherapeuticsMD Appoints Paul Bisaro And Gail Naughton To Board
3/16/2020 6:09:00 AM
TherapeuticsMD Says Takes Steps To Ensure Safety Of Employees In View Of COVID-19
2/20/2020 7:28:02 AM
TherapeuticsMD Q4 Loss Per Share $0.19 Vs Loss $0.72 Last Year
2/13/2020 6:34:39 AM
TherapeuticsMD And Afaxys Pharma, LLC Enter Agreement To Expand Access To ANNOVERA In US
2/3/2020 6:32:00 AM
TherapeuticsMD Announces Submission Of NDA Prior Approval Efficacy Supplement To FDA For Lower Dose Of BIJUVA